UNASSIGNED: An online systematic review of MEDLINE, Embase, PubMed, and the Cochrane Library from inception to January 7, 2022, was completed. Studies outlining the care of a patient with acrometastases of the hand were included. Data extracted included age, sex, site of primary tumor and metastasis, presence of other metastases, time from primary diagnosis to acrometastasis diagnosis, misdiagnosis, treatment, and survival.
UNASSIGNED: Between 1889 and present, 871 lesions were described in 676 patients who met the inclusion criteria. There was no predilection for hand dominance or site of previous trauma. The mean age among patients was 59.5 (1.5-91) years, and male sex was more common (64.6%). The most common primary cancer source was the lung (39.2%), followed by the kidney (10.8%). The distal phalanx was the most frequently cited tumor location (33.7%). Mean survival after diagnosis of acrometastasis was 6.3 months (0.25-50) ± 11.5 months.
UNASSIGNED: Acrometastasis remains an uncommon presentation of metastatic disease with poor prognosis. Treatment currently focuses on pain management and optimizing functional outcomes. Our review led to the development of 7 treatment recommendations when managing these patients.
未经评估:MEDLINE在线系统评价,Embase,PubMed,从成立到2022年1月7日的Cochrane图书馆已经完成。包括概述手部转移患者护理的研究。提取的数据包括年龄,性别,原发肿瘤和转移部位,存在其他转移,从初次诊断到肢端转移诊断的时间,误诊,治疗,和生存。
未经批准:从1889年到现在,在676例符合纳入标准的患者中描述了871个病变。没有对手优势或先前创伤部位的偏爱。患者的平均年龄为59.5(1.5-91)岁,男性更为常见(64.6%)。最常见的原发癌来源是肺(39.2%),其次是肾脏(10.8%)。远端指骨是最常见的肿瘤位置(33.7%)。诊断为肢端转移后的平均生存期为6.3个月(0.25-50)±11.5个月。
UNASSIGNED:转移仍然是转移性疾病的罕见表现,预后不良。目前,治疗的重点是疼痛管理和优化功能结果。我们的审查导致在管理这些患者时制定了7项治疗建议。